for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sarepta Therapeutics Inc

SRPT.O

Latest Trade

85.77USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

72.05

 - 

158.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Sarepta Therapeutics Announces Positive Functional Results From SRP-9003 (Myo-101) Gene Therapy Trial To Treat Limb-Girdle Muscular Dystrophy Type 2E, Or Beta-Sarcoglycanopathy

Oct 4 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS ANNOUNCES POSITIVE FUNCTIONAL RESULTS FROM THE SRP-9003 (MYO-101) GENE THERAPY TRIAL TO TREAT LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E, OR BETA-SARCOGLYCANOPATHY.SAREPTA THERAPEUTICS INC - SIGNIFICANT REDUCTION IN CREATINE KINASE MAINTAINED OVER NINE MONTHS.SAREPTA THERAPEUTICS INC - IMPROVEMENTS ON FUNCTIONAL MEASURES SEEN IN ALL THREE PARTICIPANTS.SAREPTA THERAPEUTICS - NO NEW SAFETY SIGNALS WERE OBSERVED AND SAFETY PROFILE SEEN TO DATE SUPPORTS ABILITY TO DOSE ESCALATE IN NEXT COHORT OF STUDY.

Sarepta Therapeutics Receives Complete Response Letter From The U.S. Food And Drug Administration For Golodirsen New Drug Application

Aug 19 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE US FOOD AND DRUG ADMINISTRATION FOR GOLODIRSEN NEW DRUG APPLICATION.SAREPTA THERAPEUTICS INC - CRL GENERALLY CITES TWO CONCERNS.SAREPTA THERAPEUTICS INC - SAREPTA WILL IMMEDIATELY REQUEST A MEETING WITH FDA TO DETERMINE NEXT STEPS..SAREPTA THERAPEUTICS INC - CRL CITES CONCERNS ABOUT RISK OF INFECTIONS RELATED TO INTRAVENOUS INFUSION PORTS AND RENAL TOXICITY.SAREPTA - RENAL TOXICITY WITH GOLODIRSEN WAS OBSERVED IN PRE-CLINICAL MODELS AT DOSES THAT WERE TEN-FOLD HIGHER THAN DOSE USED IN CLINICAL STUDIES.SAREPTA THERAPEUTICS INC - RENAL TOXICITY WAS NOT OBSERVED IN STUDY 4053-101, ON WHICH APPLICATION FOR GOLODIRSEN WAS BASED..SAREPTA - OVER COURSE OF REVIEW, AGENCY DID NOT RAISE ANY ISSUES SUGGESTING NON-APPROVABILITY OF GOLODIRSEN, INCLUDING ISSUES THAT FORMED BASIS OF CRL.SAREPTA - GOT CRL FOR NDA SEEKING ACCELERATED APPROVAL OF GOLODIRSEN INJECTION FOR DMD TREATMENT IN PATIENTS WITH CONFIRMED MUTATION AMENABLE TO EXON 53 SKIPPING.

Sarepta Therapeutics Comments On Erroneous Submission To Us FDA Adverse Event Reporting System

Aug 8 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS COMMENTS ON ERRONEOUS SUBMISSION TO US FDA ADVERSE EVENT REPORTING SYSTEM (FAERS).SAREPTA THERAPEUTICS INC - INFORMED EARLIER TODAY THAT AN ADVERSE EVENT REPORT WAS ERRONEOUSLY SUBMITTED TO FDA'S ADVERSE EVENT REPORTING SYSTEM.SAREPTA THERAPEUTICS - INVESTIGATION TO DATE INDICATES REPORT WAS NOT SUBMITTED TO FAERS DATABASE BY A CO'S EMPLOYEE OR STUDY'S PRINCIPAL INVESTIGATOR.SAREPTA THERAPEUTICS INC - DRUG SAFETY MONITORING BOARD RECOMMENDED STUDY CONTINUE UNINTERRUPTED.SAREPTA THERAPEUTICS INC - ADVERSE EVENT REPORT SUBMISSION REPORTED A CASE OF RHABDOMYOLYSIS IN A PARTICIPANT IN SAREPTA'S STUDY SRP-9001-102.SAREPTA THERAPEUTICS INC - NO STOPPING RULE IN STUDY 102 WAS TRIGGERED.SAREPTA THERAPEUTICS - PARTICIPANT IN STUDY SRP-9001-102 WAS HOSPITALIZED FOR OBSERVATION, DISCHARGED FOLLOWING DAY & TEST RESULTS RETURNED TO BASELINE.SAREPTA THERAPEUTICS INC - STUDY DRUG SAFETY MONITORING BOARD REVIEWED ISSUE AND RECOMMENDED SRP-9001-102 STUDY CONTINUE UNINTERRUPTED.

Sarepta Therapeutics Q2 Non-GAAP Loss Per Share $0.83

Aug 7 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q2 NON-GAAP LOSS PER SHARE $0.83.Q2 REVENUE $94.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $90.9 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-1.37 -- REFINITIV IBES DATA.

Sarepta Therapeutics Reports Q1 Non-GAAP Loss Per Share $0.75

May 8 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q1 NON-GAAP LOSS PER SHARE $0.75.Q1 REVENUE $87 MILLION VERSUS REFINITIV IBES ESTIMATE OF $86.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-1.69 -- REFINITIV IBES DATA.Q1 GAAP LOSS PER SHARE $1.07.

Paragon Announces Expansion Of Its Strategic Collaboration In Manufacturing Design And Operation With Sarepta Therapeutics

April 15 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::PARAGON - ANNOUNCES EXPANSION OF ITS STRATEGIC COLLABORATION IN MANUFACTURING DESIGN AND OPERATION WITH GENE THERAPY LEADER SAREPTA THERAPEUTICS.PARAGON - WILL EXPLORE POTENTIAL FOR A JV WITH SAREPTA IN MANUFACTURING NEW GENE THERAPY CANDIDATES IN A DEDICATED FACILITY..

Sarepta Therapeutics Exercises Option To Acquire Myonexus

April 5 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS INC - EXERCISED OPTION TO ACQUIRE MYONEXUS.SAREPTA THERAPEUTICS INC - SAREPTA IS NOW SOLE STOCKHOLDER OF MYONEXUS..

Sarepta Therapeutics Announces Pricing Of $375 Million Public Offering Of Common Stock

March 5 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS ANNOUNCES PRICING OF $375.0 MILLION PUBLIC OFFERING OF COMMON STOCK.PRICED UNDERWRITTEN PUBLIC OFFERING OF AGGREGATE OF 2.6 MILLION SHARES OF ITS COMMON STOCK AT $144.00 PER SHARE.

Sarepta Therapeutics Announces Proposed $350 Mln Public Offering Of Common Stock

March 5 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS ANNOUNCES PROPOSED $350,000,000 PUBLIC OFFERING OF COMMON STOCK.SAREPTA THERAPEUTICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING PRINCIPALLY FOR CONTINUATION AND INITIATION OF FURTHER CLINICAL TRIALS, OTHERS.

Sarepta Therapeutics Reports Q4 NON-GAAP Loss Per Share Of $0.85

Feb 27 (Reuters) - Sarepta Therapeutics Inc <SRPT.O>::SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2018 AND FULL-YEAR 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q4 NON-GAAP LOSS PER SHARE $0.85.Q4 REVENUE $84.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $86 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-1.04 -- REFINITIV IBES DATA.Q4 GAAP LOSS PER SHARE $2.05.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up